Pulmicort (Asthma) - Forecast and Market Analysis to 2023
GlobalData has released its new PharmaPoint Drug Evaluation report, “Pulmicort (Asthma) - Forecast and Market Analysis to 2023”. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
AstraZeneca’s Pulmicort is an ICS therapy that was originally launched in 1997, and is used prophylactically for the maintenance treatment of asthma in children and adults. Its active ingredient, budesonide, is an anti-inflammatory corticosteroid with a high affinity for the corticosteroid receptor. AstraZeneca’s Pulmicort franchise includes the Pulmicort Flexhaler (budesonide) for adults and pediatric patients older than six years of age, Pulmicort Respules for children between one and eight years of age, and the Pulmicort Turbuhaler for patients with bronchial asthma.
Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Pulmicort including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Pulmicort for the top eight countries from 2013 to 2023.
Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Asthma
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of Pulmicort performance
Obtain sales forecast for Pulmicort from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)
Sales for Pulmicort in the Asthma Market
Pulmicort sales are expected to decrease from$412 million in 2013 to $141 million in 2023 with anegative Compound Annual Growth Rate (CAGR)of 10.1%.
Major growth drivers for Pulmicort in the Asthmamarket over the forecast period include:
Pulmicort, like all ICSs, is a gold standard ofasthma therapy and is of central importance insecuring control in patients with persistentdisease.
Pulmicort has been used since the 1990s andhas a well-known long-term safety profile.
Pulmicort is available in several formulationsand devices, such as Flexhaler, Turbuhaler,and Respules.
Pulmicort is the preferred inhaled steroid foruse during pregnancy, given its pregnancycategory "B" rating.Conversely, major barriers to the growth ofPulmicort in the Asthma market include:
Twice-daily administration makes Pulmicortless convenient to use than the AsmanexTwisthaler or leukotriene modifiers (Singulair).
The corticosteroid ingredient in Pulmicort(budenoside) is less potent than Flovent’s(fluticasone).
The high price of Pulmicort makes it lessdesirable than its generic counterparts in anincreasingly cost-conscious society.